- Image via Wikipedia
WILMETTE, Illinois — A Northwestern University start-up has received a $2.5 million investment to commercialize technology that employs gold nanoparticles to help treat cardiovascular disease.
AuraSense LLC, founded by nanotechnology superstar and Northwestern Professor Chad Mirkin, is developing a technology that uses gold nanoparticles to sweep cholesterol out of a patient’s bloodstream, reducing the chances of heart attack or stroke.
The Role of Consultants in Tackling Healthcare Expenses
To ensure effective cost mitigation, employers can’t wait for the market to adjust — they have to punch first.
Researchers use gold and other metals as the basis of the artificial particles so they show up in medical imaging, according to a New York Times article. Â The artificial particles are designed to work like high-density lipoproteins, also known as “good cholesterol,” which can help protect the body from heart disease.
Mirkin is billed by Northwestern as the “most cited” chemist in the world and is a member of President Barack Obama’s Council of Advisors for Science and Technology. In June, he was awarded the $500,000 Lemelson-MIT prize, which recognizes scientific innovation.
Mirkin is best known for inventing the nanoparticle-based medical diagnostic assays underlying the Verigene system and Dip-Pen Nanolithography, an ultra-high-resolution molecule-based printing technique, according to Northwestern.
AuraSense has not previously reported any fund-raising to the Securities and Exchange Commission. Mirkin didn’t return a call.
Why Workflow Chaos Is Undermining Care – and What Providers Can Do About It.
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.